14 recruiting, 10 completed, 7 active not recruiting, 5 not yet recruiting. 22 Phase 2, 21 Phase 1, 3 Phase 3, 1 Early Phase 1, 1 Phase 4.
Follow Metastatic Castration-resistant Prostate Cancer (mCRPC): new trials by email Literature Review of Metastatic Castration-resistant Prostate Cancer (mCRPC) trials Research Report on Metastatic Castration-resistant Prostate Cancer (mCRPC)
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| GI-102 (CD80-IgG4 Fc-IL2v3) in Combination With Pasritamig in Patients With Metastatic Castration-resistant Prostate Cancer (mCRPC) (JET-201) GI-102, Pasritamig - Metastatic Castration-resistant Prostate Cancer (mCRPC) | Phase 1 / Phase 2 | Recruiting | GI Innovation, Inc. | 107 | 2026-10-12 | 2026-10-19 |
| Green Tea and Quercetin in Combination With Docetaxel Chemotherapy in Castration-resistant Prostate Cancer Patients green tea and quercetin + docetaxel, Placebo + docetaxel - Metastatic Castration-resistant Prostate Cancer (mCRPC) | Phase 1 / Phase 2 | Recruiting | Charles Drew University of Medicine and Science | 99 | 2026-10-01 | 2026-04-15 |
| RYZ711 Diagnostic Platform Study RYZ711, PSMA PET/CT - Prostate Cancer (Adenocarcinoma), Adenocarcinoma of the Prostate | Phase 1 / Phase 2 | Not yet recruiting | RayzeBio, Inc. | 116 | 2026-10-01 | 2026-10-19 |
| Lutetium (177Lu) DGUL Combined With Pembrolizumab in Metastatic Castration-Resistant Prostate Cancer Lutetium (177Lu) DGUL, Pembrolizumab - Metastatic Castration-resistant Prostate Cancer (mCRPC) | Phase 1 | Recruiting | Cellbion Co., Ltd. | 30 | 2026-07-29 | 2026-10-07 |
| REGN15505 (PSMAx4-1BB) Alone or in Combination With Cemiplimab or REGN4336 (PSMAxCD3) in Adult Patients With Metastatic Castration-Resistant Prostate Cancer and Clear Cell Renal Cell Carcinoma REGN15505, REGN15505+Cemiplimab, REGN15505+REGN4336 - Metastatic Castration-Resistant Prostate Cancer (mCRPC), Clear Cell Renal Cell Carcinoma (ccRCC) | Phase 1 / Phase 2 | Recruiting | Regeneron Pharmaceuticals | 265 | 2026-07-20 | 2026-09-28 |
| PROLONG (PRostateOLaparibONcombinationGcc) Study Olaparib and Abiraterone Combination - Metastatic Castration-resistant Prostate Cancer (mCRPC) | Not yet recruiting | AstraZeneca | 75 | 2026-06-30 | 2026-06-29 | |
| Study of ERW316 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors ERW316, Fulvestrant, Letrozole - Advanced HR+/HER2- Breast Cancer, Advanced CCNE1-amplified Solid Tumors | Phase 1 / Phase 2 | Withdrawn | Novartis Pharmaceuticals | 2026-06-30 | 2026-06-22 | |
| A Study to Investigate the Safety and Tolerability of Oral INR731 Single Agent or in Combination With Androgen Receptor Pathway Inhibitor (ARPI) in Patients With Metastatic Prostate Cancer INR731, Enzalutamide, Abiraterone - Metastatic Castration-resistant Prostate Cancer (mCRPC) | Phase 1 | Recruiting | Novartis Pharmaceuticals | 208 | 2026-05-25 | 2026-10-23 |
| Trial of Xaluritamig in Adults With Metastatic Castration-resistant Prostate Cancer Xaluritamig - Metastatic Castration-resistant Prostate Cancer (mCRPC) | Phase 1 | Recruiting | Amgen | 40 | 2026-04-28 | 2026-09-15 |
| 68Ga-PSMA-0057 and 177Lu-PSMA-0057 in Patients With PSMA-Positive Metastatic Castration-Resistant Prostate Cancer 68Ga-PSMA-0057, 177Lu-PSMA-0057 - Metastatic Castration-resistant Prostate Cancer (mCRPC) | Phase 1 / Phase 2 | Not yet recruiting | Chengdu StarRay Therapeutics Co., Ltd | 49 | 2025-12-30 | 2025-12-30 |
| Memantine Hydrochloride in Prostate Cancer Patients Memantine Hydrochloride - Metastatic Castration-resistant Prostate Cancer (mCRPC), Prostate Cancer | Phase 2 | Not yet recruiting | Bin Xu | 15 | 2025-11-01 | 2025-11-19 |
| Study of TY-302 Capsules Combined With Abiraterone in Patients With Metastatic Castration-resistant Prostate Cancer（mCRPC） TY-302, Abiraptor - Metastatic Castration-resistant Prostate Cancer (mCRPC) | Phase 1 / Phase 2 | Not yet recruiting | TYK Medicines, Inc | 48 | 2025-08-01 | 2025-08-05 |
| Study of Lutetium (177Lu) Vipivotide Tetraxetan in mCRPC Participants With Moderately and Severely Impaired and With Normal Renal Function AAA617, 68Ga-PSMA-11 - Metastatic Castration-Resistant Prostate Cancer (mCRPC) | Phase 2 | Active not recruiting | Novartis Pharmaceuticals | 23 | 2024-04-04 | 2026-07-10 |
| Safety and Efficacy Study of NUV-1511 in Adult Patients With Advanced Solid Tumors NUV-1511 - Advanced Solid Tumor, HER2-negative Breast Cancer | Phase 1 / Phase 2 | Active not recruiting | Nuvation Bio Inc. | 466 | 2024-03-14 | 2026-01-14 |
| A Phase II Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of YL201 in Patients With mCRPC YL201 for Injection - Metastatic Castration-resistant Prostate Cancer (mCRPC) | Phase 2 | Recruiting | MediLink Therapeutics (Suzhou) Co., Ltd. | 100 | 2024-02-22 | 2025-08-27 |
| A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004) Opevesostat, Dexamethasone, Fludrocortisone acetate - Metastatic Castration-resistant Prostate Cancer (mCRPC), Prostatic Neoplasms | Phase 3 | Recruiting | Merck Sharp & Dohme LLC | 1314 | 2023-12-18 | 2026-10-20 |
| Sipuleucel-T Based Autologous Cellular Immunotherapy for Advanced Prostate Cancer Sipuleucel-T - Metastatic Castration-Resistant Prostate Cancer (mCRPC) | Phase 1 | Active not recruiting | University of Oklahoma | 15 | 2023-11-12 | 2026-05-27 |
| Combination Study of Antibiotics With Enzalutamide (PROMIZE) Enzalutamide 40mg, Amoxicillin 500mg, Metronidazole 400mg - Metastatic Castration-Resistant Prostate Cancer (mCRPC) | Phase 1 / Phase 2 | Recruiting | Institute of Cancer Research, United Kingdom | 39 | 2023-11-02 | 2025-11-24 |
| Metastatic Castrate-Resistant Prostate Cancer Subjects Treated With PROVENGE® + One Infusion of Sipuleucel-T Sipuleucel-T Injection - Metastatic Castration-Resistant Prostate Cancer (mCRPC) | Phase 2 | Recruiting | Dendreon | 400 | 2023-10-02 | 2025-08-27 |
| A Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Dosimetry of [177Lu]Lu-PSMA-617 in Chinese Adult Male Patients With Progressive PSMA-Positive mCRPC [177Lu]Lu-PSMA-617, Best supportive/best standard of care (BS/BSOC), 68Ga-PSMA-11 - Metastatic Castration-Resistant Prostate Cancer (mCRPC) | Phase 2 | Completed | Novartis Pharmaceuticals | 62 | 2023-05-16 | 2026-09-15 |
Showing 20 of 40. Sign in to see all of them.
Prostatic Neoplasms (12) · Carcinoma, Renal Cell (4) · Carcinoma, Non-Small-Cell Lung (3) · Carcinoma, Transitional Cell (3) · Colorectal Neoplasms (3) · Squamous Cell Carcinoma of Head and Neck (3) · Uterine Cervical Neoplasms (2) · Adenocarcinoma (1) · Adenocarcinoma, Clear Cell (1) · Breast Neoplasms (1) · Carcinoma, Hepatocellular (1) · Carcinoma, Ovarian Epithelial (1) · Endometrial Neoplasms (1) · Fallopian Tube Neoplasms (1) · Head and Neck Neoplasms (1)
Neoplasms by Site (19) · Neoplasms (18) · Urogenital Diseases (18) · Male Urogenital Diseases (17) · Urogenital Neoplasms (17) · Genital Diseases (13) · Genital Diseases, Male (12) · Genital Neoplasms, Male (12) · Prostatic Diseases (12) · Neoplasms by Histologic Type (9) · Carcinoma (8) · Neoplasms, Glandular and Epithelial (8) · Female Urogenital Diseases (7) · Female Urogenital Diseases and Pregnancy Complications (7) · Adenocarcinoma (5)
enzalutamide (7) · Abiraterone Acetate (4) · Docetaxel (4) · Prednisone (4) · abiraterone (3) · Dexamethasone (2) · Injections (2) · Pluvicto (2) · cemiplimab (2) · gallium 68 PSMA-11 (2) · pembrolizumab (2) · radium Ra 223 dichloride (2) · sipuleucel-T (2) · Amoxicillin (1) · Androgen Antagonists (1)
Novartis Pharmaceuticals (5) · AstraZeneca (2) · Jiangsu HengRui Medicine Co., Ltd. (2) · Regeneron Pharmaceuticals (2) · Advanced Accelerator Applications (1) · Amgen (1) · Astellas Pharma Global Development, Inc. (1) · Avionco LLC (1) · Bayer (1) · BeiGene (1) · Bin Xu (1) · British Columbia Cancer Agency (1) · Cellbion Co., Ltd. (1) · Charles Drew University of Medicine and Science (1) · Chengdu StarRay Therapeutics Co., Ltd (1)
United States (24) · China (8) · Spain (8) · Australia (7) · South Korea (7) · Canada (6) · France (6) · United Kingdom (6) · Germany (5) · Italy (5) · Belgium (4) · Czechia (3) · Hungary (3) · Israel (3) · New Zealand (3)
Ashkan Mortezavi, MD, PhD (1) · Benjamin Lowentritt, MD (1) · Chang Wook Jeong, MD, phD (1) · Cheol Kwak, MD, phD (1) · Jan Oldenburg, Professor (1) · Johan Lindberg, PhD (1) · Johann De Bono, MD (1) · Jolene Shorr (1) · Kelly Stratton, MD (1)
PMID 32586393, PMID 34636627, PMID 35317973, PMID 35362047, PMID 35922861, PMID 37812518, PMID 38430405, PMID 39164518, PMID 39990653, PMID 40263079, PMID 40346626, PMID 41732008, PMID 41764712
2023 (3), 2025 (2), 2018 (1), U54MD007598 (1)